Valuation : Basilea Pharmaceutica AG

Market Cap 811M 1.01B 866M 743M 1.4B 96.4B 1.4B 9.61B 3.75B 48.58B 3.79B 3.71B 161B P/E 2026 *
19.2x
P/E 2027 * 19.7x
Enterprise Value 661M 823M 706M 605M 1.14B 78.56B 1.14B 7.83B 3.06B 39.6B 3.09B 3.02B 131B EV / Sales 2026 *
2.54x
EV / Sales 2027 * 2.21x
Free-Float
91.73%
Yield 2026 *
-
Yield 2027 * -
1 day-0.15%
1 week-0.30%
Current month+26.01%
1 month+24.81%
3 months+22.24%
6 months+18.48%
Current year+19.56%
1 week 63.4
Extreme 63.4
66.5
1 month 50.4
Extreme 50.4
66.5
Current year 47.8
Extreme 47.8
66.5
1 year 44.7
Extreme 44.7
66.5
3 years 32
Extreme 32
66.5
5 years 29.55
Extreme 29.55
66.5
10 years 29.28
Extreme 29.28
95.35
Manager TitleAgeSince
Chief Executive Officer 61 19/04/2018
Director of Finance/CFO 52 10/04/2019
Chief Tech/Sci/R&D Officer 62 01/05/2018
Director TitleAgeSince
Director/Board Member 70 29/11/2011
Chairman 71 09/04/2013
Director/Board Member 73 27/04/2017
Date Insider Type Main position Quantity % Market Cap.
29/5/26 Sell -400 0.0030%
25/2/26 Fiscal year 1,500 0.0113%
20/2/26 Sell 600 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
-0.15%-0.30% - - 1.01B
Average -0.15%
Weighted average by Cap. -0.15%

Financials

2026 *2027 *
Net sales 261M 324M 278M 239M 450M 30.98B 451M 3.09B 1.21B 15.61B 1.22B 1.19B 51.67B 271M 337M 289M 248M 467M 32.15B 468M 3.2B 1.25B 16.2B 1.26B 1.24B 53.63B
Net income 53.56M 66.64M 57.21M 49.04M 92.38M 6.36B 92.65M 634M 248M 3.21B 250M 245M 10.62B 44.43M 55.29M 47.46M 40.68M 76.64M 5.28B 76.86M 526M 206M 2.66B 208M 203M 8.81B
Net Debt -150M -187M -160M -137M -259M -17.84B -260M -1.78B -695M -8.99B -701M -686M -29.75B -214M -266M -228M -196M -369M -25.4B -370M -2.53B -989M -12.8B -998M -977M -42.36B
Logo Basilea Pharmaceutica AG
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Employees
200
Date Price Change Volume
27/08/26 CHF 65.40 -0.15% 42,086
26/08/26 CHF 65.50 +0.31% 48,673
25/08/26 CHF 65.30 +0.93% 46,885
24/08/26 CHF 64.70 +0.15% 64,913
21/08/26 CHF 64.60 -1.52% 73,634
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
65.40CHF
Average target price
88.50CHF
Spread / Average Target
+35.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BSLN Stock